the use of the anti-cd3-activated cytolytic cells as effectors in anti-cd3 heterodimer-mediated lysis of tumor cells may be a novel approach to the therapy of cancer , and a comparison with the well-studied ril-2/lymphokine-activated killer ( lak ) system is discussed .
C0007634
the
C1536403
cytolytic